• Improving Outcomes with Targeted FcRn Receptor Inhibition for the Full Spectrum of Patients with gMG

    CME Satellite Symposium at the 2026 AANEM Annual Meeting

  • 1. A 42-year-old woman with AChR antibody–positive gMG takes pyridostigmine and prednisone 15 mg/day. Her MG-ADL score is 3. She reports persistent fatigue, weight gain, and missed workdays. Based on current expert consensus care goals, what is the most appropriate treatment target?*
  • 2. A 38-year-old man has 4 months of ptosis and diplopia that worsen by evening, plus fatigable proximal arm weakness. AChR and MuSK antibodies are negative by radioimmunoassay (RIA). Repetitive nerve stimulation (RNS) at 3 Hz in the abductor digiti minimi is normal. What is the most appropriate next step?*
  • 3. In the ADAPT SERON trial of efgartigimod in AChR antibody–negative gMG, which statement best describes the placebo-adjusted MG-ADL change at week 4?*
  • 4. A 29-year-old woman with MuSK antibody–positive gMG has bulbar and neck weakness. She takes mycophenolate mofetil and hopes to become pregnant within the next year. Which management step is most appropriate?*
  • Which of the following best describes your title?*

  • Please rate the extent to which this activity met the following objectives:

  • Learning Objectives
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • This educational activity will result in a change in my practice behavior.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
  • Attestation to time spent on activity: AcademicCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

  • AcademicCME thanks you for your participation in this activity. All information provided improves the scope and purpose of our programs.

  • Should be Empty: